Literature DB >> 26137209

Psoriatic arthritis: latest treatments and their place in therapy.

Eun Jin Kang1, Arthur Kavanaugh2.   

Abstract

Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that may affect peripheral and axial joints, entheses, skin and nails, and other organs. Treatment with nonsteroidal anti-inflammatory drugs, steroid and disease-modifying antirheumatic drugs had been the backbone of traditional management of PsA for many years. However, improvement in our understanding of immunopathogenesis of PsA has led to new immunomodulatory therapies. Introduction of novel agents has raised the bar for treatment and helped drive research into additional therapeutic options.

Entities:  

Keywords:  disease-modifying antirheumatic drugs; immunomodulatory therapies; psoriatic arthritis

Year:  2015        PMID: 26137209      PMCID: PMC4480547          DOI: 10.1177/2040622315582354

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  78 in total

Review 1.  Use of methotrexate in patients with psoriatic arthritis.

Authors:  A Ceponis; A Kavanaugh
Journal:  Clin Exp Rheumatol       Date:  2010-10-28       Impact factor: 4.473

2.  Successful use of tocilizumab in a patient with psoriatic arthritis.

Authors:  Michael Hughes; Hector Chinoy
Journal:  Rheumatology (Oxford)       Date:  2013-02-18       Impact factor: 7.580

3.  Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.

Authors:  Karen Minde Fagerli; Elisabeth Lie; Désirée van der Heijde; Marte Schrumpf Heiberg; Synøve Kalstad; Erik Rødevand; Knut Mikkelsen; Ase Stavland Lexberg; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2013-04-05       Impact factor: 19.103

4.  A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Authors:  A D Fraser; A W R van Kuijk; R Westhovens; Z Karim; R Wakefield; A H Gerards; R Landewé; S D Steinfeld; P Emery; B A C Dijkmans; D J Veale
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

5.  Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

Authors:  Peter Schafer
Journal:  Biochem Pharmacol       Date:  2012-01-10       Impact factor: 5.858

6.  Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

Authors:  Wolfram Sterry; Jean-Paul Ortonne; Bruce Kirkham; Olivier Brocq; Deborah Robertson; Ronald D Pedersen; Joanne Estojak; Charles T Molta; Bruce Freundlich
Journal:  BMJ       Date:  2010-02-02

Review 7.  Janus kinases in immune cell signaling.

Authors:  Kamran Ghoreschi; Arian Laurence; John J O'Shea
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

8.  Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.

Authors:  J R Curtis; T Beukelman; A Onofrei; S Cassell; J D Greenberg; A Kavanaugh; G Reed; V Strand; J M Kremer
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 9.  Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.

Authors:  S Fénix-Caballero; E J Alegre-del Rey; R Castaño-Lara; F Puigventós-Latorre; J M Borrero-Rubio; J F López-Vallejo
Journal:  J Clin Pharm Ther       Date:  2013-04-17       Impact factor: 2.512

10.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.

Authors:  Bente Glintborg; Mikkel Ostergaard; Niels Steen Krogh; Martin Dehn Andersen; Ulrik Tarp; Anne Gitte Loft; Hanne M Lindegaard; Mette Holland-Fischer; Henrik Nordin; Dorte Vendelbo Jensen; Christian Holkmann Olsen; Merete Lund Hetland
Journal:  Arthritis Rheum       Date:  2013-05
View more
  16 in total

Review 1.  Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East.

Authors:  Mohamed Bedaiwi; Ibrahim A Al-Homood; Ayman El-Garf; Imad Uthman; Nancy Sunna; Reenad Nassier; Haytham Mohamed; Jamal Al Saleh
Journal:  Rheumatol Int       Date:  2019-05-27       Impact factor: 2.631

Review 2.  Targeting IL-17 in psoriatic arthritis.

Authors:  Elizabeth A Wang; Erika Suzuki; Emanual Maverakis; Iannis E Adamopoulos
Journal:  Eur J Rheumatol       Date:  2017-11-10

Review 3.  Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis.

Authors:  Hanan Al Rayes; Mansour Alazmi; Suzan Attar; Khaled Alderaan; Mushabab Alghamdi; Nayef Alghanim; Ahmed Alhazmi; Nadeer Alkhadhrawi; Mohammad Almohideb; Zeyad Alzahrani; Mohamed Bedaiwi; Hussein Halabi
Journal:  Rheumatol Int       Date:  2021-10-30       Impact factor: 2.631

4.  Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Authors:  Peter Nash; Iain B McInnes; Philip J Mease; Howard Thom; Matthias Hunger; Andreas Karabis; Kunal Gandhi; Shephard Mpofu; Steffen M Jugl
Journal:  Rheumatol Ther       Date:  2018-03-31

5.  Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.

Authors:  A B Gottlieb; J F Merola; K Reich; F Behrens; P Nash; C E M Griffiths; W Bao; P Pellet; L Pricop; I B McInnes
Journal:  Br J Dermatol       Date:  2021-07-14       Impact factor: 11.113

6.  Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).

Authors:  Hidehisa Saeki; Hidemi Nakagawa; Ko Nakajo; Taeko Ishii; Yoji Morisaki; Takehiro Aoki; Gregory S Cameron; Olawale O Osuntokun
Journal:  J Dermatol       Date:  2016-10-11       Impact factor: 4.005

Review 7.  Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.

Authors:  Martin Bergman; Amy Lundholm
Journal:  Arthritis Res Ther       Date:  2017-03-20       Impact factor: 5.156

8.  Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.

Authors:  Philip J Mease; Chitra Karki; Mei Liu; Arthur Kavanaugh; Christopher T Ritchlin; Doquyen Hoa Huynh; Jacqueline B Palmer; Jeffrey D Greenberg
Journal:  RMD Open       Date:  2018-04-25

9.  Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.

Authors:  Timo Purmonen; Kari Puolakka; Devarshi Bhattacharyya; Minal Jain; Janne Martikainen
Journal:  Cost Eff Resour Alloc       Date:  2018-11-16

Review 10.  Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis.

Authors:  Martin Bergman; Amy Lundholm
Journal:  Rheumatology (Oxford)       Date:  2018-03-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.